Intravenous Immunoglobulin (IVIg) Market is Rising at a Healthier CAGR of 5.9% During Forecast to 2023
Intravenous Immunoglobulin (IVIg), a
compound comprising of immune proteins (globulins) is administered into the
bloodstream to treat patients with the inefficient or damaged immune systems. IVIg
suffices the required antibodies by the human body to fight out the immune
deficiency, and the consequent infectious attacks. Immunodeficiency Disorder
could be a hereditary issue (Primary disorders), or caused due to the exposure
to infections, mainly through bodily fluids, along with the cancer drugs and
chemotherapy, aging is one of the key risk factor too that could put someone at
greater risk of a damaged immune system.
Market Research
Future (MRFR) has recently published a study report giving out the complete
market forecast up to 2023. In its analysis, MRFR asserts that the global Intravenous Immunoglobulin Market Trends growing further will
reach USD 8337.2 Million by 2023, registering 5.9% CAGR during 2017
to 2023.
The demand for
IVIg therapies to treat acquired and primary immunodeficiency diseases are on a
rise as it is considered as a highly effective and the only available treatment
method. Besides, sedentary lifestyle habits such as consumption of saturated fats
sugar and salt, high alcohol consumption and les physical activities are
resulting in the prevalence of such diseases. The growing prevalence of
lifestyle related health issues like antibody deficiency disorders and obesity will
add to the market growth during the evaluation period.
Major Players:
·
Abeona Therapeutics
·
BDI Pharma
·
China Biologic Products
·
Biotest AG
·
Grifols Inc
·
CSL Behring
Intravenous
Immunoglobulin Market – Competitive Analysis
The global IVIg market is fiercely competitive with the
presence of several large and small players operating in the market. These
market players acquire promising companies to expand in the fast-growing
markets, focusing on improving their market performance. The market structure
is dynamic due to the acquisition of local manufactures by the multinational
companies. Strategies like product innovations and technologies are creating
strong investment opportunities for the market players.
Intravenous
Immunoglobulin Market – Segments
·
Global Intravenous Immunoglobulin (IVIg) Market has been segmented on the
basis of type which comprise IgA (sub segments- IgA1 and IgA2), IgD, IgE, IgG,.
·
On the basis of application it segmented into CIDP (Progressive,
Recurrent, Monophasic), Hypogammaglobulinemia (sub segments- AGM1, AGM2, AGM3,
AGM4, AGM5, AGM6), Multifocal Motor Neuropathy, Immunodeficiency diseases (sub
segments- X-linked agammaglobulinemia (XLA), common variable immunodeficiency
(CVID), severe combined immunodeficiency), Primary Humoral Immunodeficiency
(Subsegments- B cell (antibody) deficiencies, T cell deficiencies, Combination
B and T cell deficiencies, Defective phagocytes, Complement deficiencies,
Unknown (idiopathic)), Myasthenia Gravis (Sub segments- generalized myasthenia
gravis, ocular myasthenia gravis, Congenital myasthenia gravis, Transient
neonatal myasthenia gravis), Guillain-Barre syndrome (Sub segments- Acute
inflammatory demyelinating polyradiculoneuropathy (AIDP), Miller Fisher
syndrome (MFS), Acute motor axonal neuropathy (AMAN)and acute motor-sensory axonal
neuropathy (AMSAN)), Kawasaki disease, ITP (Sub segments- acute and chronic),
and others.
Intravenous
Immunoglobulin Market – Geographical Analysis
On the other hand, Europe, the world’s
second-largest market for IVIg, is fostered by the high per capita income and
robust healthcare penetration in the region. The strong market growth in the countries
like Germany & France drives the regional market growth, large scale.
Attributing to the increasing investment in healthcare and rising number of
patients with immune system diseases, the market is projected to register a
phenomenal CAGR during the forecast period.
Asia Pacific market for the Intravenous
Immunoglobulin is expected to perceive an exponential growth. Owing to the huge
population and the burgeoning medical treatment market, India & China drive
the regional market growth. Vietnam, Thailand, and Malaysia among the other
South East Asian countries are projected to contribute significantly to the
regional market growth. With the growing Medical Tourism markets in India &
Malaysia the APAC region will register a significant CAGR during the review
period.
Related Reports:
Flight Tracking
System Market Research Report – Forecast to 2023
Digital
Pathology Market Research Report - Forecast To 2023
NOTE : Our team of
researchers are studying Covid19 and its impact on various industry verticals
and wherever required we will be considering covid19 footprints for a better
analysis of markets and industries. Cordially get in touch for more details.
Comments
Post a Comment